Proteomics for precision medicine: Next-generation testing to indicate future cardiovascular risk and improve outcomes
Proteomics for precision medicine: Next-generation testing to
indicate future cardiovascular risk and improve outcomes
Proteomic testing can reveal multiple answers to clinical questions that allow providers to better predict, monitor, and prevent the escalation of cardiovascular disease (CVD). This allows providers to move the needle away from the practice of late-stage treatment and toward treating at-risk patients sooner and before a major cardiovascular (CV) event.
Topics covered include:
- The capabilities of proteomics
- How comprehensive protein detection technology can accurately predict major cardiovascular events
- How proteomic testing can ultimately improve outcomes
Nelson Trujillo, MD
Cardiologist
Boulder Heart at Anderson Medical Center
Rosalyn Gill, PhD
Vice President, Medical Affairs
SomaLogic, Inc.
Todd Johnson
Executive Vice President, Diagnostics
Business Unit
SomaLogic, Inc.
Proteomics for precision medicine: Next-generation testing to indicate future cardiovascular risk and improve outcomes
A presentation by Nelson Trujillo, MD, Rosalyn Gill, PhD, and Todd Johnson
More webinars
WebinarUsing non-hypothesized based approaches for biomarker development
Current biomarkers are only moderately predictive in identifying individuals with mild traumatic brain injury or concussion. Therefore, more accurate diagnostic markers are needed for sport-related concussion (SRC).
WebinarAssessment of variability and normalization methods using the plasma 7K SomaScan® Assay v4.1
In this webinar, the speakers present the largest technical assessment of this platform to date based on a study of 2,050 samples across 22 plates.
WebinarThe proteomics of aging: how technology is advancing research
Please join us to hear four experts discuss the present challenges and opportunities for proteomics in aging research: Eric Morgen, COO of BioAge Labs; Paola Sebastiani, faculty biostatistician at Tufts Medical Center and PI on the Longevity Consortium; Birgit Schilling, associate professor, Buck Institute for Research on Aging; and Alessandro Ori, group leader at the Leibniz Institute on Aging.